Pegfilgrastim biosimilar is under clinical development by Curateq Biologics and currently in Phase II for Chemotherapy Induced Neutropenia. According to GlobalData, Phase II drugs for Chemotherapy Induced Neutropenia have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pegfilgrastim biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pegfilgrastim biosimilar overview

BP14 (Pegfilgrastim) is under development for the treatment of chemotherapy induced neutropenia. The drug candidate is administered through subcutaneous route. It acts by targeting granulocyte colony stimulating factor receptor (GCSFR).

Curateq Biologics overview

Curateq Biologics, a subsidiary of Aurobindo Pharma Ltd, is engaged in the research and development of recombinant biologics, especially in areas of biosimilars drug substance development and proteins formulations. Curateq Biologics is headquartered in Hyderabad, Telangana, India.

For a complete picture of Pegfilgrastim biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.